Red Yeast Rice
14 benefits mapped to clinical evidence across supplements.
Dose per serving from products
247 products in our catalogue print how much Red Yeast Rice a serving holds.
Most common: 1 g to 2.5 g, 39% of 247 products.
| Dose per serving | Products |
|---|---|
| 25 mg or less | 4 |
| 25 mg to 50 mg | 14 |
| 50 mg to 100 mg | 9 |
| 100 mg to 250 mg | 11 |
| 250 mg to 500 mg | 34 |
| 500 mg to 1 g | 78 |
| 1 g to 2.5 g | 97 |
Dose per serving from research
49 study groups in 40 studies say how much Red Yeast Rice participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 g to 2.5 g, 31% of 49 study groups.
| Daily dose | Study groups |
|---|---|
| 2.5 mg to 5 mg | 4 |
| 5 mg to 10 mg | 10 |
| 10 mg to 25 mg | 2 |
| 25 mg to 50 mg | 0 |
| 50 mg to 100 mg | 2 |
| 100 mg to 250 mg | 12 |
| 250 mg to 500 mg | 0 |
| 500 mg to 1 g | 0 |
| 1 g to 2.5 g | 15 |
| 2.5 g to 5 g | 4 |
Commonly used together
29 of 49 study groups took Red Yeast Rice with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Berberine | 11 |
| Coenzyme Q10 | 11 |
| Policosanol | 11 |
| Folic Acid | 6 |
| Phytosterols | 4 |
| Astaxanthin | 3 |
| Niacin | 3 |
| Probiotics | 3 |
Benefit Evidence
LDL/inflammation −26–47%
Heart events/death −44–64%
Fatigue/activities unchanged
Cholesterol lowering (-49 mg/dL)
Insulin/glucose improvement
Blood pressure drop (-10 mmHg)
Cholesterol lowering (-49 mg/dL)
Insulin/glucose improvement
Blood pressure drop (-10 mmHg)
Research sources
Cholesterol (42)
- Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial
PubMed ID: 19528562
Statin-intolerant patients: RYR + lifestyle substantially lowered LDL (~35 mg/dL) vs placebo in RCT.
- Low Dose Monacolin K Combined with Coenzyme Q10, Grape Seed, and Olive Leaf Extracts Lowers LDL Cholesterol in Patients with Mild Dyslipidemia: A Multicenter, Randomized Controlled Trial
PubMed ID: 37375586
Low-dose (3 mg) monacolin-containing supplement lowered LDL ~17% in mild dyslipidemia (multicenter RCT).
- Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome
PubMed ID: 30021394
Monacolin K + CoQ10 produced −16% TG reduction in metabolic syndrome trial.
- The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols
PubMed ID: 20153154
Pediatric crossover trial (RYR+policosanol) produced large LDL reductions (−25.1%) over 8 weeks.
- Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients
PubMed ID: 22113535
12‑month randomized study in elderly statin‑intolerant patients: LDL −31% (large, durable effect).
- LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia
PubMed ID: 22527287
RYR + policosanol + artichoke supplement reduced TG by ~12.2% at 16 weeks.
- Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study
PubMed ID: 23266743
Dose study showed ~20–25 mg/dL LDL reductions at 4 weeks with RYR-containing preparation.
- Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
PubMed ID: 22998978
Large RCT of berberine+red yeast rice pill produced ~31.7% LDL reduction over 6 months — robust effect (combination product).
- A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial
PubMed ID: 23815518
16‑week RCT of RYR‑containing supplement lowered LDL ≈14.3% vs placebo.
- Effects of a Novel Nutraceutical Combination (Aquilea Colesterol(®)) on the Lipid Profile and Inflammatory Biomarkers: A Randomized Control Trial
PubMed ID: 31035469
Phytosterol + RYR + antioxidant supplement lowered LDL ~19.7% vs placebo at 3 months.
- Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study
PubMed ID: 28704936
Nutraceutical with RYR+berberine+chitosan reduced non‑HDL, LDL and ApoB by ~12–19% at 12 weeks.
- Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q(10) on lipid levels: a randomized, double-blind, placebo controlled study
PubMed ID: 28579756
Large randomized trial with monacolin K (10 mg) showed ~26% LDL reduction at 4 weeks — very strong lipid-lowering evidence.
- Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment
PubMed ID: 30420184
In statin‑intolerant CAD patients, adding Armolipid Plus (contains RYR) helped many reach LDL goals — pragmatic evidence of LDL efficacy in clinical setting.
- Relationship between adiponectin and leptin, and blood lipids in hyperlipidemia patients treated with red yeast rice
PubMed ID: 23860021
Small uncontrolled study: large LDL and TC decreases reported with RYR over 8 weeks (uncontrolled).
- A Randomized Clinical Efficacy Trial of Red Yeast Rice (Monascus pilosus) Against Hyperlipidemia
PubMed ID: 30871361
Monacolin K‑rich RYR randomized trial reduced TC and LDL over 3 months vs control formulations.
- A multicenter study of nutraceutical drinks for cholesterol (evaluating effectiveness and tolerability)
PubMed ID: 22385548
Duplicate entry: RYR drink reduced LDL/TC rapidly (see above).
- The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk
PubMed ID: 29951651
10 mg monacolin K supplement produced large LDL reductions (~−36.6 mg/dL) in controlled comparison.
- Safety and Efficacy of NC120 for Improving Lipid Profile: A Double Blind Randomized Controlled Trial
PubMed ID: 31073102
NC120 (RYR + others) significantly reduced total and LDL cholesterol vs placebo; RYR part of multi-ingredient mix.
- Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial
PubMed ID: 27339779
Crossover RCT of combined nutraceutical (including RYR) produced meaningful LDL and TC reductions and decreased hs‑CRP.
- Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction
PubMed ID: 18549841
Large long-term RCT showed LDL/TC lowering alongside major event and mortality reductions.
- Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X
PubMed ID: 17196275
Xuezhikang lowered LDL by ~26% in cardiac syndrome X patients (randomized trial).
- Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina
PubMed ID: 15653117
Dose-comparison in angina patients showed rapid and large TC and LDL reductions in 2 weeks.
- [Intervention of xuezhikang on patients of acute coronary syndrome with different levels of blood lipids]
PubMed ID: 15658647
12‑week trial in ACS patients produced significant TC/TG/LDL‑C reductions.
- Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease
PubMed ID: 15313947
Significant reduction in postprandial triglyceride AUC in coronary patients after 6 weeks.
- Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease
PubMed ID: 12881451
Xuezhikang lowered atherogenic Lp(a), hs‑CRP and postprandial TG, and reduced LDL in CHD patients.
- Effectiveness and safety of red yeast rice predominated by monacolin K β-hydroxy acid form for hyperlipidemia treatment and management
PubMed ID: 35473348
Monacolin K acid added to lifestyle produced marked LDL, total and non‑HDL reductions over 60 days.
- Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement
PubMed ID: 9989685
Duplicate strong RCT evidence (see above).
- Red yeast rice induces less muscle fatigue symptom than simvastatin in dyslipidemic patients: a single center randomized pilot trial
PubMed ID: 28521773
RYR reduced LDL ≈33% comparable to simvastatin in dyslipidemic patients.
- No additional cholesterol-lowering effect observed in the combined treatment of red yeast rice and Lactobacillus casei in hyperlipidemic patients: A double-blind randomized controlled clinical trial
PubMed ID: 27838874
RYR significantly lowered LDL in hyperlipidemic patients; probiotic addition had no added effect.
- Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: A double blind, placebo controlled randomized trial
PubMed ID: 25879228
Combo product lowered LDL ≈24% in metabolic‑syndrome subjects (attribution partly to olive extract).
- HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study
PubMed ID: 20636227
Double-blind RCT (HypoCol) lowered LDL ~23% vs placebo over 16 weeks in Caucasians.
- Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance
PubMed ID: 20102918
In statin‑intolerant patients RYR lowered LDL ≈30%, similar to pravastatin.
- Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red Yeast Rice Extract) (Randomized, Double-Blind, Placebo-Controlled Study)
PubMed ID: 33525601
Nutraceutical (RYR + probiotic) lowered LDL −25.7% and TC −16.7% at 12 weeks (combined product).
- Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial
PubMed ID: 28687937
Two-month combined supplement (RYR + phytosterols + l‑tyrosol) improved LDL/TC and endothelial function.
- Phytosterols, red yeast rice, and lifestyle changes instead of statins: a randomized, double-blinded, placebo-controlled trial
PubMed ID: 23816039
One-year trial in statin-refusers using RYR showed sustained LDL/TC/TG reductions over 1 year.
- Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease
PubMed ID: 12801622
Xuezhikang in CHD patients produced large fasting LDL/TC and postprandial TG reductions.
- A Randomized, Double-Blinded, Placebo-Controlled, Clinical Study of the Effects of a Nutraceutical Combination (LEVELIP DUO(®)) on LDL Cholesterol Levels and Lipid Pattern in Subjects with Sub-Optimal Blood Cholesterol Levels (NATCOL Study)
PubMed ID: 33066334
Phytosterol + RYR RCT reduced LDL ~20% and ApoB, demonstrating lipid profile improvement (combined product).
- Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on blood lipids in human subjects with hyperlipidemia
PubMed ID: 19786378
Nattokinase+RYR group had TG reductions (~−15%) over 6 months (combined product).
- ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia
PubMed ID: 27143594
Large double-blind RCT reported ~29% LDL and ~30% non‑HDL reductions with RYR-containing capsule.
- Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial
PubMed ID: 29655700
Multi-ingredient fermented RYR product improved fasting/postprandial lipids vs placebo; RYR among actives.
- Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study
PubMed ID: 25499939
Multicenter RCT of Xuezhikang (RYR extract) showed ~27% LDL reduction vs placebo — strong direct evidence.
- Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial
PubMed ID: 23866314
8‑week double‑blind trial in physicians: LDL ~22% and TC ~15% reductions with characterized RYR product.
Heart health (19)
- Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina
PubMed ID: 15653117
Rapid reductions in CRP and LDL in stable angina patients — supports cardiac risk reduction mechanisms.
- Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
PubMed ID: 19699071
RCT showing LDL lowering and endothelial function improvement with a nutraceutical containing RYR.
- Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q(10) on lipid levels: a randomized, double-blind, placebo controlled study
PubMed ID: 28579756
Rapid and substantial LDL reductions with monacolin K‑containing product are highly relevant to cardiovascular wellness.
- NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial
PubMed ID: 30471555
Improvements in lipids, PCSK9, inflammation and arterial stiffness in HIV patients using RYR‑containing nutraceutical.
- Potential protective effect of long-term therapy with Xuezhikang on left ventricular diastolic function in patients with essential hypertension
PubMed ID: 19552598
72‑week Xuezhikang trial improved diastolic function and reduced inflammatory/fibrotic biomarkers vs placebo.
- Middle-Term Dietary Supplementation with Red Yeast Rice Plus Coenzyme Q10 Improves Lipid Pattern, Endothelial Reactivity and Arterial Stiffness in Moderately Hypercholesterolemic Subjects
PubMed ID: 27055107
Improvements in LDL, endothelial reactivity and PWV suggest cardiovascular wellness benefit.
- Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome
PubMed ID: 30021394
Monacolin K + CoQ10 improved LDL, systolic BP and TG in metabolic syndrome — broad CV risk improvements.
- Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial
PubMed ID: 19528562
Statin-intolerant RCT: substantial LDL lowering without increased CPK/pain — clinically relevant heart-risk improvement.
- Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study
PubMed ID: 25499939
Xuezhikang (RYR extract) RCT produced substantial LDL/non‑HDL reductions — established heart-risk factor improvements.
- ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia
PubMed ID: 27143594
Large double‑blind trial with RYR-containing capsule produced LDL/non‑HDL reductions comparable to moderate statin therapy.
- Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease
PubMed ID: 12801622
Xuezhikang in CHD patients greatly lowered LDL and postprandial TG — directly relevant to heart disease risk.
- Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease
PubMed ID: 12881451
Xuezhikang reduced Lp(a), hs‑CRP and postprandial TG in CHD patients — heart-relevant biomarkers improved.
- Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease
PubMed ID: 15313947
Improved FMD and reduced inflammation/postprandial TG in coronary patients — supports cardiovascular health.
- [Intervention of xuezhikang on patients of acute coronary syndrome with different levels of blood lipids]
PubMed ID: 15658647
Improved endothelial function, lowered CRP and lipids in ACS patients — overall cardiovascular benefit.
- Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X
PubMed ID: 17196275
Improvements in LDL, CRP, ET‑1 and exercise tolerance in cardiac syndrome X indicate direct cardiac benefits.
- Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS)
PubMed ID: 17312447
Xuezhikang produced large, clinically relevant reductions in major coronary events, non‑fatal/fatal MI and all‑cause death — strongest heart‑health evidence.
- Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction
PubMed ID: 18549841
Large RCT post‑MI demonstrated marked reductions in repeat coronary events and mortality → strong heart‑health evidence.
- Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS)
PubMed ID: 19602720
Elderly hypertensive post‑MI subgroup showed fewer coronary events and CHD death with Xuezhikang.
- HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study
PubMed ID: 20636227
Placebo‑controlled LDL lowering in Caucasian sample supports cardiovascular risk modification.
Vascular health (9)
- Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial
PubMed ID: 29655700
Fermented RYR product improved markers of endothelial damage vs placebo.
- Middle-Term Dietary Supplementation with Red Yeast Rice Plus Coenzyme Q10 Improves Lipid Pattern, Endothelial Reactivity and Arterial Stiffness in Moderately Hypercholesterolemic Subjects
PubMed ID: 27055107
Monacolin K + CoQ10 improved arterial stiffness (PWV) and endothelial reactivity in RCT.
- NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial
PubMed ID: 30471555
Reduced arterial stiffness (aPWV −6%) and lower PCSK9/inflammation in HIV patients after RYR‑containing therapy.
- Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
PubMed ID: 19699071
Improved FMD in RCT with RYR‑containing nutraceutical shows better endothelial/arterial function.
- Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X
PubMed ID: 17196275
Marked ET‑1 reduction (−47%) and improved exercise tolerance indicate improved arterial vasomotor health.
- Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease
PubMed ID: 15313947
FMD improvements indicate better endothelial/arterial function in coronary patients.
- Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial
PubMed ID: 28687937
Combined supplement improved endothelial function (FMD) — surrogate for artery health.
- Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS)
PubMed ID: 17312447
Large long‑term trial (Xuezhikang) produced major reductions in coronary events — strong evidence of arterial benefit.
- [Intervention of xuezhikang on patients of acute coronary syndrome with different levels of blood lipids]
PubMed ID: 15658647
FMD, NO increases and ET‑1 decreases support improved arterial health in ACS patients.
Inflammation (9)
- Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X
PubMed ID: 17196275
Xuezhikang reduced CRP median by ~38% (log −44%) in a randomized trial — clear anti‑inflammatory signal.
- Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina
PubMed ID: 15653117
CRP decreased rapidly (within 24 h) and substantially over 2 weeks in stable angina patients.
- [Intervention of xuezhikang on patients of acute coronary syndrome with different levels of blood lipids]
PubMed ID: 15658647
CRP decreased and ET‑1 improved in ACS patients after 12 weeks.
- Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease
PubMed ID: 15313947
Marked reduction in hs‑CRP and improved endothelial function after 6 weeks in coronary patients.
- Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease
PubMed ID: 12881451
Xuezhikang reduced hs‑CRP significantly in CHD patients (RCT).
- A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters
PubMed ID: 25001663
3‑month combo pill with RYR lowered inflammatory markers (hs‑CRP, IL‑6, TNF‑α) vs placebo — multi-ingredient.
- Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial
PubMed ID: 27339779
Crossover RCT of combined nutraceutical including RYR reduced hs‑CRP by ~18% vs placebo.
- NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial
PubMed ID: 30471555
Nutraceutical in HIV patients reduced hs‑CRP by ~14% and other inflammatory markers.
- Effects of a Novel Nutraceutical Combination (Aquilea Colesterol(®)) on the Lipid Profile and Inflammatory Biomarkers: A Randomized Control Trial
PubMed ID: 31035469
Phytosterol+RYR+antioxidant trial decreased hs‑CRP (p=0.021) alongside LDL lowering.
Blood circulation (9)
- NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial
PubMed ID: 30471555
In HIV patients, RYR+berberine pill improved arterial stiffness (aPWV −6%) and inflammation — supports improved circulation.
- Middle-Term Dietary Supplementation with Red Yeast Rice Plus Coenzyme Q10 Improves Lipid Pattern, Endothelial Reactivity and Arterial Stiffness in Moderately Hypercholesterolemic Subjects
PubMed ID: 27055107
Monacolin-containing supplement improved endothelial reactivity and reduced arterial stiffness (PWV) in RCT.
- Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial
PubMed ID: 29655700
Multi-ingredient fermented RYR improved endothelial damage markers vs placebo (sICAM-1, sVCAM-1, sE-selectin).
- Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial
PubMed ID: 28687937
Combined supplement including RYR improved flow-mediated dilation (endothelial function) vs placebo.
- Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease
PubMed ID: 15313947
Significant improvement in flow‑mediated dilation (FMD) in coronary patients after 6 weeks → direct evidence of improved endothelial function/circulation.
- [Intervention of xuezhikang on patients of acute coronary syndrome with different levels of blood lipids]
PubMed ID: 15658647
Improved FMD and favorable NO/ET‑1 changes in ACS patients after 12 weeks → supports improved vascular function.
- Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X
PubMed ID: 17196275
Xuezhikang reduced vasoconstrictor ET‑1 markedly and improved exercise tolerance — direct vascular/flow benefit.
- Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: A Pilot Randomized Trial
PubMed ID: 30723735
Nutraceutical with RYR improved FMD compared with comparator in pilot RCT.
- Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
PubMed ID: 19699071
Flow‑mediated dilation improved vs placebo — direct evidence of better endothelial‑mediated blood flow.
Fat burn (6)
- Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome
PubMed ID: 30021394
Triglycerides decreased ~16% in metabolic syndrome RCT with Monacolin K + CoQ10 adjunct.
- LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia
PubMed ID: 22527287
RYR‑containing supplement reduced TG by ~12.2% at 16 weeks in moderate hypercholesterolemia.
- Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
PubMed ID: 22998978
Berberine + RYR pill lowered triglycerides ~19.5% and LDL ~31.7% — supports beneficial effects on lipid/fat metabolism.
- Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study
PubMed ID: 28704936
Nutraceutical (RYR+berberine+chitosan) reduced non‑HDL and LDL significantly — supports fat/lipoprotein metabolism.
- Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on blood lipids in human subjects with hyperlipidemia
PubMed ID: 19786378
Nattokinase+RYR group had triglyceride reductions (~−15%) over 6 months (combined product).
- Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease
PubMed ID: 12801622
Xuezhikang greatly lowered fasting and postprandial triglycerides in CHD patients — supports fat metabolism.
Healthy aging (3)
- Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction
PubMed ID: 18549841
Large long-term RCT showed reduced total and cardiovascular mortality and fewer coronary events after MI → supports aging-related outcomes.
- Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS)
PubMed ID: 17312447
Large RCT (Xuezhikang) showed major coronary event and all-cause mortality reductions over ~4 years — strong ageing/cardiovascular longevity signal.
- Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS)
PubMed ID: 19602720
Randomized elderly post‑MI subgroup showed fewer recurrent coronary events and CHD death → relevant to healthy aging.
Wellbeing (3)
- Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X
PubMed ID: 17196275
Reduced inflammation/ET‑1 and improved exercise tolerance could translate to improved wellbeing.
- Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS)
PubMed ID: 17312447
Large mortality and MI reductions with Xuezhikang imply meaningful clinical benefit to wellbeing.
- Red yeast rice induces less muscle fatigue symptom than simvastatin in dyslipidemic patients: a single center randomized pilot trial
PubMed ID: 28521773
Patients on RYR reported less fatigue and preserved activity vs simvastatin → supports better short‑term wellbeing.
Metabolism (3)
- Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome
PubMed ID: 30021394
Randomized trial in metabolic syndrome showed LDL, systolic BP and triglyceride improvements — direct metabolic benefit.
- The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk
PubMed ID: 29951651
High-monacolin (10 mg) supplement reduced LDL/TC and produced a small fasting glucose improvement over 1 month.
- Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: A double blind, placebo controlled randomized trial
PubMed ID: 25879228
In metabolic syndrome subjects, combo reduced LDL, OxLDL and BP → supports broader metabolic improvements (combo product).
Blood pressure (2)
- Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome
PubMed ID: 30021394
Monacolin K + CoQ10 adjunct to diet reduced systolic BP by ~5.2 mmHg in metabolic syndrome RCT.
- Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: A double blind, placebo controlled randomized trial
PubMed ID: 25879228
Combined RYR + olive extract lowered systolic (~10 mmHg) and diastolic (~7 mmHg) BP in metabolic syndrome subjects (combination product).
Antioxidant (2)
- Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: A double blind, placebo controlled randomized trial
PubMed ID: 25879228
Combined RYR+olive lowered OxLDL (and BP) in metabolic syndrome; antioxidant effect likely but partly attributable to olive extract.
- A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA(2), in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial
PubMed ID: 28673363
RYR + olive extract reduced oxidised LDL and Lp‑PLA2 in metabolic syndrome subjects → supports antioxidant effect (combination product).
Weight management (1)
- Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial
PubMed ID: 18613992
Lifestyle + RYR + fish oil arm produced meaningful weight loss (−5.5%) vs simvastatin; RYR part of multi-component program.
Endurance (1)
- Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X
PubMed ID: 17196275
Improved exercise tolerance (cardiac syndrome X) alongside improvements in vascular biomarkers — direct stamina evidence.
Energy & Fatigue (1)
- Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X
PubMed ID: 17196275
Xuezhikang improved exercise tolerance in cardiac syndrome X — suggests improved exertional capacity/energy.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Red Yeast Rice
Search all364 products whose verified label declares Red Yeast Rice — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.